Glofit-GemOx Superior to Rituximab-GemOx in Treating Relapsed/Refractory DLBCL

The annual hybrid congress of the European Hematology Association was held in Madrid from June 13-16, where a study was presented showing that Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) was superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study examined the efficacy and safety of Glofit-GemOx versus R-GemOx in patients with R/R DLBCL who had undergone one or more prior lines of therapy.

Overview of the Study

A total of 274 patients were randomly assigned to receive either Glofit-GemOx or R-GemOx, with 183 patients receiving Glofit-GemOx and 91 receiving R-GemOx. The primary analysis, conducted as of March 29, 2023, showed a significant overall survival benefit with Glofit-GemOx versus R-GemOx. Median overall survival was not reached for Glofit-GemOx versus nine months for R-GemOx at a median follow-up of 11.3 months. An independent review committee-assessed progression-free survival and complete remission rate demonstrated a significant benefit for Glofit-GemOx.

Follow-up analysis was conducted once all patients had completed therapy as of February 16, 2024, with a median follow-up period of 20.7 months. Glofit-GemOx continued to demonstrate superior median overall survival, median progression-free survival, and complete remission rates compared to R-GemOx. Adverse event rates were higher with Glofit-Gemox than R-GemOx, including grade 3 to 4 and grade 5 adverse events and serious adverse events, though the rates were similar after adjustment for exposure differences.

Understanding Glofitamab and GemOx

Glofitamab is a new antibody that has been developed to treat cancer. It works by attaching itself to cancer cells and stopping them from growing. Gemcitabine and oxaliplatin are chemotherapy drugs that are often used together to treat various types of cancer, including DLBCL. These drugs work by damaging the DNA of cancer cells, making it hard for them to divide and grow.

Glofitamab in combination with GemOx showed clinically significant improvement in overall survival, as well as key secondary end points, and the benefits were reinforced with an additional 11 months of follow-up. Given these findings, Glofit-GemOx may become the new standard of care for patients with R/R DLBCL.

The Future of Glofitamab and GemOx

The results of this study are very exciting for patients with R/R DLBCL. Currently, there are limited treatment options available for these patients, but Glofit-GemOx has demonstrated a significant improvement in overall survival and progression-free survival rates. Further research and clinical trials are needed to fully understand the potential of Glofitamab and GemOx in treating other types of cancer or in combination with other therapies. It is hoped that this study will lead the way to new and more effective treatments for patients with DLBCL and other forms of cancer.

Conclusion

The study presented at the annual hybrid congress of the European Hematology Association showed that Glofitamab plus gemcitabine and oxaliplatin is superior to rituximab (R)-GemOx for treating relapsed/refractory diffuse large B-cell lymphoma. The study demonstrated a significant overall survival benefit, with Glofit-GemOx continuing to show superior results compared to R-GemOx over a median follow-up period of 20.7 months. Despite higher rates of adverse events, the benefits of Glofit-GemOx make it a promising new standard of care for patients with R/R DLBCL. Further research and clinical trials are needed to fully understand the potential of Glofitamab and GemOx in treating other types of cancer or in combination with other therapies.

Keywords:

Glofit-GemOx
Rituximab-GemOx
Relapsed/refractory diffuse large B-cell lymphoma
Glofitamab
Gemcitabine and oxaliplatin
Overall survival
Progression-free survival
Adverse events
Standard of care
Clinical trials

Originally Post From https://www.hematologyadvisor.com/news/glofitamab-gemox-superior-to-rituximab-gemox-for-lymphoma/

Glofitamab GemOx Outperforms Rituximab GemOx in Lymphoma